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Abstract
Objectives
We aimed to perform genetic testing and clinical data of patients with 
Congenital Myasthenic Syndrome, a rare disorder caused by mutations in 
genes encoding molecules expressed in the neuromuscular junction and 
constitutes fatigable muscle weakness.
Materials & Methods
Sixteen patients were screened in Taban Clinic, Tehran, Iran from 2014 to 
2015 for the hot spot mutations in known CMSs genes (CHRNE, CHAT, 
RAPSN) based on clinical data. PCR was performed and then direct DNA 
sequencing was done for mutation identification. 
Results
Most patients represented the criteria of Congenital Myasthenic Syndrome 
in view of early ptosis, motor delay, normal mental development, easy 
fatigability, decrement in repetitive nerve stimulation test of EMG-NCV 
and a negative result for antibody against of acetylcholine receptor. No 
variations were found in the mutational analysis of the CHRNE gene. 
Analysis of CHAT gene revealed c.358G>A (P. A120T) variation in 9 
patients. In the gene RAPSN, polymorphism c.456T>C(  P.Y152Y) and 
polymorphism c.193-15C>T (IVS1-15C>T) were identified in 11 and one 
patients, respectively. 
Conclusion
The common founder mutations of involved genes in CMSs could be very 
rare among ethnic Iranian. Screening of the entire genes would be efficient 
to distinguish the specific mutations in specific ethnicity. 
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Introduction
Congenital Myasthenic syndromes (CMSs) are 
considered as an extremely rare heterogeneous group 
of disorders that caused dysfunction of neuromuscular 
transmission. In CMSs, impaired neural transmission 
has identified in pre-synaptic, synaptic and most 
frequently in post-synaptic stages. Mainly, post-
synaptic CMSs are caused by deficiency or kinetic 
abnormalities of acetylcholine receptor (AChR) and are 
much more frequent than pre-synaptic or synaptic form. 
The cardinal presentations of CMSs are hypotonia, 
episodic apnea, ptosis and fatigability that appear in 
early infancy or childhood. Patients have a significant 
variability in the clinical phenotype, onset, course of 
the disease, and response to treatment (1, 2).
Accurate molecular mechanisms arising from the 
genetic defect help confirmation of the diagnosis and 
also determine a proper therapy (3, 4). 
To date, 25 different genes encoding proteins involved 
in neuromuscular junction have been identified in 
association with CMSs. Mutations in the epsilon subunit 
of the nicotinic acetylcholine receptor determined the 
commonest cause but the RAPSN gene was more likely 
to be the second causative mutant gene for the disease. 
RAPNS gene plays a pivotal role in AChR clustering 
in the post-synaptic membrane of the neuromuscular 
junction (2). The missense c.264C>A, p. Asn88Lys 
mutation in the RAPSN is the fundamental defect 
reported particularly among European (1).
On the other hand, a possible mutation in CHAT which 
is first responsible gene for presynaptic CMS has been 
proposed to be scrutinized according to the literature. 
CHAT encodes the enzyme choline acetyltransferase 
and its deficiency is known for causing CMS with 
apnoeic episodes (EA) (5).
The objectives of our study tackled the screening 
for founder mutations involving in CHRNE, CHAT, 
and RAPSN. It has also compared the frequency of 
founder mutation p. Asn88Lys in RAPSN in different 
populations.
Materials & Methods
The study cases consisted of 16 individuals (10 
males and 6 females) referred from the Department 
of Pediatric Neurology, Mofid Children’s Hospital 
Tehran, Iran from 2014 to 2015. The diagnosis of CMS 
was performed on the basis of the clinical features, the 
absence of anti-AChR antibodies, electromyography 
examination including; single fiber test and the positive 
familiar history (3).
In neurological examination, the patients had motor 
delay, Ptosis and muscle weakness that was worst 
with activity and lack of sleep. Deep tendon reflexes 
were diminished and plantar reflexes were downward. 
We evaluated all patients with electromyography 
examination and the result showed more than 10% 
decrement that confirmed the diagnosis of Myasthenia. 
Furthermore, antibodies against the Ach choline 
receptors were negative; therefore, they are not the 
cases of Myasthenia gravis. 82% of our patients were 
offspring of consanguineous marriage and the sign 
and symptoms were started in early weeks and months 
of life. On the other hand, the other diagnoses about 
motor delay and lower motor neuron diseases such 
as mitochondrial disorders, and congenital myopathy 
hypothyroidism were ruled out.
In genetic study, blood samples were obtained from 
the patients and genomic DNA was isolated using 
blood DNA extraction kit (MBST, Tehran, Iran). Target 
mutation analysis for previously reported mutations in 
11 and 12 of CHRNE, exon 5 of CHAT and, exon 2 of 
RAPSN gene was performed with primers in Table 1. In 
addition, Primer sequence for exon 2 of RAPSN gene 
was ordered (6).
 The PCR reactions were performed in a thermal cycler 
(Techne, Genius, UK) for 5 min at 95 °C followed by 
35 cycles of denaturation for 1 min at 94 °C, annealing 
for 1 min depending on melting temperature of primers 
(Table 2), primer extension for 30 sec at 72 °C with 
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final 5 min extension at 72 °C. The amplified PCR 
products were sequenced by ABI3100 system. Finch 
TV software was used to align and analyze the DNA 
sequences and compared with gene bank.
Results
We screened in all patients for the common 
mutations CHRNE  p. Glu443LysfsTer64  and 
CHAT p. lle305Thr.Subsequently, we sequenced 
RAPSN gene for the known mutations p. Asn88Lys, 
p. Arg91Cys, p. Glu94Lys, p. Arg164Cys, and p. 
Val165Met widely reported. Although patients’ 
clinical phenotype is compatible with CMS, no 
pathogenic mutations were found by sequencing 
CHRNE, CHAT, and RAPSN. 
Of the 16 patients recruited, nine patients identified 
with variation c.3558G>A (p. A120T) in CHAT. 
In the gene RAPSN two previously published 
polymorphisms were detected: c.456T>C(  
P.Y152Y)  and c.193-15C>T (IVS1-15C>T) (3). 
Precisely, among 13 patients with polymorphism 
c.456T>C; 11 were homozygous and 2 were 
heterozygous. Only one patient harbored the frequent 
polymorphism c.193-15C>T (IVS1-15C>T) in the 
homozygous state. As an illustration, Figure 1 




Figure1. Sequence electropherogram showing a polymorphism c.456T>C RAPSN in                                      
heterozygous state 
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Figure 1. Sequence electropherogram showing a polymorphism c.456T>C RAPSN in heterozygous state
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Discussion
Screening of hotspot mutations in CHRNE and CHAT 
and RAPSN have been extensively reported by many 
studies. Precisely, Targeted assessments were included 
mutations: (c.1327 delG; exon 12) (7) in CHRNE, 
(c.914T>C; exon 5) (8) in CHAT and (c.264C>A, exon 
2) (9) in RAPSN. 
The CHRNE mutation c.1327delG were found in up to 
50% of individuals of European Roma (7, 10). Whereas 
the RAPSN c.264C>A mutation due to a founder effect 
accounting for about 90% of patients’ origination from 
Europe (11). Table 3 reveals the distribution of mutation 
c.264C>A, p. Asn88Lys in RAPSN across geographical 
regions.
Besides, the vast majority of variations in CHRNE 
and RAPSN genes were dispersed over the entire gene. 
To date, in the Mayo clinic cohort of CMS patients of 
mostly European origin, CHRNE and RAPSN mutations 
were found 51% and 14%, respectively (6). Different 
frequencies were found in Israel cohort, where 20% had 
mutations in CHREN, 37% in RAPSN, and 3% in CHAT 
(12). The mutation c.-38A>G RAPSN occurs in a cohort 
of Iranian and/or Iraqi Jewish origin patients (13).
No pathogenic mutations were detected in our 
candidate gene approach. The variations were de-
tected in CHRNE and CHAT genes did not show 
any amino acids exchanges. The exonic SNP 
456T>C,rs7111873  in RAPSN does not under-
lie amino acid substitution (3, 11). The intronic 
SNP IVS1-15C>T may result from transcriptional 
or conformational protein changes (14), but this 
would need more investigation. Therefore, none of 
the known polymorphisms were found to be signifi-
cantly related to CMSs.As accordance with the high 
rate of hotspot mutations c.1327delG, c.264C>A of 
CHRNE and RAPSN, respectively, in European de-
scent and also our similarities to European in terms 
of ethnicity, we postulated that the mutations will 
be observed at least 5% in our series. 
The frequencies of SNPs rs7111873 of RAPSN and 
rs3810950 in CHAT which found in our cohort differ 
from the SNP frequencies reported in Iranome (http://
iranome.com/) including 0.7175 in rs711873 of RAPSN 
and 0.2594 of CHAT. There are two possible reasons 
for differentiation: First, CMS is a rare condition; larger 
sample size may facilitate finding the known European 
founder mutations in our population (9). Second, Iran 
is one of the most multi-ethnic states. It consists of 
different ethnicities including Lure, Turk, Mazani, Fars, 
and Kurd and other subpopulations. Thus, to obtain 
ethnic-specific mutation for CMSs expanded genetic 
tests and centralized clinical management would help 
to advance research opportunities.
A negative screening for the hotspot mutations does not 
rule out the possibility of underlying the mutations of 
the genes. Further studies that screen CHRNE, CHAT, 
and RAPSN genes full sequence are warranted to throw 
light and elucidate the mutational basis of CMSs in 
Iranian. The use of next-generation sequencing (NGS) 
method in spite of being expensive (12), may help to 
identify the mutated genes. 
In conclusion, the outcome of this study has extended 
the genotype spectrum of Iranian with CMS, conferring 
a way to a more effective method for career detection, 
genetic diagnosis and counseling of Iranian patients 
with CMS disorders.  
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